Month: November 2022

Muresan, Bogdan; Mamolo, Carla; Cappelleri, Joseph C.; Leip, Eric; Viqueira, Andrea; Heeg, Bart published an article in 2021, the title of the article was An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia.Name: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile And the article contains the following content:

Bosutinib, nilotinib and dasatinib are approved for the treatment of patients with newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML). In the absence of head-to-head comparisons between second-generation tyrosine kinase inhibitors (TKIs), the objective of this study was to indirectly compare the efficacy of bosutinib with nilotinib and dasatinib in first-line (1L) CP-CML. Cross-trial heterogeneity in terms of patient baseline characteristics and imatinib dose escalation are difficult to adjust for in network meta-analyses and anchored matching-adjusted indirect treatment comparisons (MAICs). Therefore, an unanchored MAIC was performed using patient level data from bosutinib (BFORE trial) and published aggregated data from nilotinib (ENESTnd) and dasatinib (DASISION) trials. After matching, cytogenetic and mol. responses, and disease progression, after a min. follow-up of 24 mo were compared between nilotinib vs. bosutinb and dasatinib vs. bosutinib. The comparison of nilotinib vs. bosutinib resulted in no statistically significant differences for MMR at and by 24 mo, MR4 by 24 mo, MR4.5 at and by 24 mo, CCyR by 24 mo, and disease progression, however, a decreased odds of MR4 at 24 mo in favor of bosutinib vs. nilotinib was observed The comparison of dasatinib vs. bosutinib by 24 mo resulted in no statistically significant differences for MMR, disease progression, and CCyR, however a decreased odds of MR4.5 in favor of bosutinib vs. dasatinib was observed Overall, in these analyses bosutinib demonstrates equivalent efficacy to nilotinib and dasatinib in the treatment of patients with newly diagnosed CP-CML. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Name: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to bosutinib nilotinib dasatinib chronic phase myeloid leukemia, chronic myeloid leukemia, bosutinib, dasatinib, first line, nilotinib, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Name: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Lu, Xiaoxiao; Guan, Anqi; Chen, Xi; Xiao, Jian; Xie, Mingxuan; Yang, Baishuang; He, Shuya; You, Shaojin; Li, Wei; Chen, Qiong published an article in 2020, the title of the article was mPRa mediates P4/Org OD02-0 to improve the sensitivity of lung adenocarcinoma to EGFR-TKIs via the EGFR-SRC-ERK1/2 pathway.Synthetic Route of 380843-75-4 And the article contains the following content:

The discovery of epidermal growth factor receptor (EGFR) mutations has made EGFR tyrosine kinase inhibitors (EGFR-TKIs) a milestone in the treatment for advanced non-small cell lung cancer (NSCLC). However, patients lacking EGFR mutations are not sensitive to EGFR-TKI treatment and the emergence of secondary resistance poses new challenges for the targeted therapy of lung cancer. In this study, we identified that the expression of membrane progesterone receptor a (mPRa) was associated with EGFR mutations in lung adenocarcinoma patients and subsequently affected the efficacy of EGFR-TKIs. Progesterone (P4) or its derivative Org OD02-0 (Org), which is mediated by mPRa, increases the function of EGFR-TKIs to suppress the proliferation, migration, and invasion of lung adenocarcinoma cells in vitro and in vivo. In addition, the mPRa pathway triggers delayed resistance to EGFR-TKIs. Mechanistic investigations demonstrated that the mPRa pathway can crosstalk with the EGFR pathway by activating nongenomic effects to inhibit the EGFR-SRC-ERK1/2 pathway, thereby promoting antitumorigenic effects. In conclusion, our data describe an essential role for mPRa in improving sensitivity to EGFR-TKIs, thus rationalizing its potential as a therapeutic target for lung adenocarcinomas. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Synthetic Route of 380843-75-4

The Article related to lung adenocarcinoma membrane progesterone receptor a egfr mutation, egfr mutations, egfr-tkis, lung adenocarcinoma, mprα, sensitivity, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Synthetic Route of 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On March 28, 2013, Kolbe, Ludger; Scherner, Cathrin published a patent.Related Products of 53788-12-8 The title of the patent was Heterocyclocarbonyl aminothiazoles, cosmetic or dermatological preparations containing said heterocyclocarbonyl aminothiazoles, and use thereof to combat or prevent undesired pigmentation of the skin. And the patent contained the following:

The invention relates to cosmetic and dermatol. preparations having an effective content of one or more heterocyclocarbonyl aminothiazoles of formula I and to the use thereof for the cosmetic or dermatol. treatment and/or prophylaxis of undesired skin pigmentation. Compounds of formula I wherein R1 is morpholino, piperidin-1-yl, piperazin-1-yl, etc.; R2 is H, (un)branched C1-24 alkyl, (un)branched C1-24 alkenyl, etc.; X is H, Ph, 2,4-dihydroxyphenyl, etc.; Y is H, aryl, COO-aryl, etc.; as free bases and their cosmetic and dermatol. acceptable salts, are claimed. Example compound II was prepared by thioamidation of 4-morpholinecarbonyl chloride with thiourea followed by cyclocondensation of the resulting N-morpholinocarbonylthiourea with 2-bromo-2′,4′-bismethoxycarbonyloxyacetophenone. All the invention compounds were evaluated for their ability to inhibit pigmentation. From the assay, it was determined that example compound II exhibited 97% of inhibition. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).Related Products of 53788-12-8

The Article related to heterocyclocarbonyl aminothiazole preparation cosmetic dermatol treatment pigmentation, Heterocyclic Compounds (More Than One Hetero Atom): Thiazoles, Isothiazoles and other aspects.Related Products of 53788-12-8

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On March 28, 2013, Kolbe, Ludger; Scherner, Cathrin published a patent.Computed Properties of 53788-12-8 The title of the patent was Heterocyclocarbonyl aminothiazoles, cosmetic or dermatological preparations containing said heterocyclocarbonyl aminothiazoles, and use thereof to combat or prevent undesired pigmentation of the skin. And the patent contained the following:

The invention relates to cosmetic and dermatol. preparations having an effective content of one or more heterocyclocarbonyl aminothiazoles of formula I and to the use thereof for the cosmetic or dermatol. treatment and/or prophylaxis of undesired skin pigmentation. Compounds of formula I wherein R1 is morpholino, piperidin-1-yl, piperazin-1-yl, etc.; R2 is H, (un)branched C1-24 alkyl, (un)branched C1-24 alkenyl, etc.; X is H, Ph, 2,4-dihydroxyphenyl, etc.; Y is H, aryl, COO-aryl, etc.; as free bases and their cosmetic and dermatol. acceptable salts, are claimed. Example compound II was prepared by thioamidation of 4-morpholinecarbonyl chloride with thiourea followed by cyclocondensation of the resulting N-(morpholinocarbonyl)thiourea with 2-bromo-2′,4′-bismethoxycarbonyloxyacetophenone. All the invention compounds were evaluated for their ability to inhibit pigmentation. From the assay, it was determined that example compound II exhibited 97% of inhibition. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).Computed Properties of 53788-12-8

The Article related to heterocyclocarbonyl aminothiazole preparation cosmetic dermatol treatment pigmentation, Heterocyclic Compounds (More Than One Hetero Atom): Thiazoles, Isothiazoles and other aspects.Computed Properties of 53788-12-8

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On November 20, 2021, Garrosa-Jimenez, Javier; Sanchez Carro, Yolanda; Ovejero-Benito, Maria C.; del Sastre, Eric; Garcia, Antonio G.; Lopez, Manuela G.; Lopez-Garcia, Pilar; Cano-Abad, Maria F. published an article.Recommanded Product: N-((4-(4-Phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide The title of the article was Intracellular calcium and inflammatory markers, mediated by purinergic stimulation, are differentially regulated in monocytes of patients with major depressive disorder. And the article contained the following:

The P2X7 receptor (P2X7R) is a ligand-gated ion channel that is being recognized as a major player in neuropsychiatric disorders such as Major Depressive Disorder (MDD). P2X7R activation is triggered by high extracellular ATP concentrations, leading to channel opening and inducing an increase in cytosolic calcium concentration ([Ca2+]c), that activates the inflammatory pathway. Those receptors are expressed not only in CNS cells but also in peripheral blood cells, where they are activated in response to inflammatory mols. such as bacterial lipopolysaccharide (LPS). LPS induced-tissue damage promotes an elevation of extracellular ATP, triggering the NRLP3-inflammasome assembly and activation that, sequentially, induces caspase-1 cleavage and IL-1尾 processing and secretion. In this context, we attempt to understand the role of P2X7R in [Ca2+]c homeostasis regulation, inflammasome expression and its pharmacol. modulation in MDD. For this purpose, monocytes were isolated from peripheral blood of MDD patients and [Ca2+]c was monitored with the intracellular probe Fura-2. Our results point out to P2X7R as the responsible of the Ca2+ imbalance, as well as TNF-伪-dependent activation of caspase-1 in MDD patients. In addition, P2X7R blockade with its specific antagonist, JNJ-47965567, reduces the Ca2+ entry upon Bz-ATP exposure. Altogether, our results point that MDD patients have both, Ca2+ homeostasis alteration and an inflammatory status, which promote an independent-inflammasome activation of caspase-1. Therefore, we propose the pharmacol. modulation of P2X7R as a therapeutic approach against MDD symptoms. The experimental process involved the reaction of N-((4-(4-Phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide(cas: 1428327-31-4).Recommanded Product: N-((4-(4-Phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide

The Article related to human mdd calcium inflammatory marker purinergic stimulation monocyte, calcium homeostasis, inflammation, major depression disorder, p2x7 receptors, Mammalian Pathological Biochemistry: Nervous System and Psychiatric Diseases and other aspects.Recommanded Product: N-((4-(4-Phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Zhao, Ya-Fei; Ren, Wen-Jing; Zhang, Ying; He, Jin-Rong; Yin, Hai-Yan; Liao, Yang; Rubini, Patrizia; Deussing, Jan M.; Verkhratsky, Alexei; Yuan, Zeng-Qiang; Illes, Peter; Tang, Yong published an article in 2022, the title of the article was High, in Contrast to Low Levels of Acute Stress Induce Depressive-like Behavior by Involving Astrocytic, in Addition to Microglial P2X7 Receptors in the Rodent Hippocampus.Electric Literature of 1428327-31-4 And the article contains the following content:

Extracellular ATP (ATP) in the brain is suggested to be an etiol. factor of major depressive disorder (MDD). It has been assumed that stress-released ATP stimulates P2X7 receptors (Rs) at the microglia, thereby causing neuroinflammation; however, other central nervous system (CNS) cell types such as astrocytes also possess P2X7Rs. In order to elucidate the possible involvement of the MDD-relevant hippocampal astrocytes in the development of a depressive-like state, we used various behavioral tests (tail suspension test [TST], forced swim test [FST], restraint stress, inescapable foot shock, unpredictable chronic mild stress [UCMS]), as well as fluorescence immunohistochem., and patch-clamp electrophysiol. in wild-type (WT) and genetically manipulated rodents. The TST and FST resulted in learned helplessness manifested as a prolongation of the immobility time, while inescapable foot shock caused lower sucrose consumption as a sign of anhedonia. We confirmed the participation of P2X7Rs in the development of the depressive-like behaviors in all forms of acute (TST, FST, foot shock) and chronic stress (UCMS) in the rodent models used. Further, pharmacol. agonists and antagonists acted in a different manner in rats and mice due to their diverse potencies at the resp. receptor orthologs. In hippocampal slices of mice and rats, only foot shock increased the current responses to locally applied dibenzoyl-ATP (Bz-ATP) in CA1 astrocytes; in contrast, TST and restraint depressed these responses. Following stressful stimuli, immunohistochem. demonstrated an increased co-localization of P2X7Rs with a microglial marker, but no change in co-localization with an astroglial marker. Pharmacol. damage to the microglia and astroglia has proven the significance of the microglia for mediating all types of depression-like behavioral reactions, while the astroglia participated only in reactions induced by strong stressors, such as foot shock. Because, in addition to acute stressors, their chronic counterparts induce a depressive-like state in rodents via P2X7R activation, we suggest that our data may have relevance for the etiol. of MDD in humans. The experimental process involved the reaction of N-((4-(4-Phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide(cas: 1428327-31-4).Electric Literature of 1428327-31-4

The Article related to acute stress depression astrocyte microglia receptor rodent hippocampus, p2x7 receptor, extracellular atp, hippocampus, major depression, mouse, rat, Mammalian Pathological Biochemistry: Nervous System and Psychiatric Diseases and other aspects.Electric Literature of 1428327-31-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Mrachkovskaya, L. B.; Anisimova, O. S.; Turchin, K. F.; Yakhontov, L. N. published an article in 1976, the title of the article was Formation of the bis(N-methylpiperazide) of monothiooxalic acid from 3-(N-methylpiperazinyl)propionic acid under conditions of the Zelinsky reaction.Formula: C8H18Cl2N2O2 And the article contains the following content:

The title compound I was obtained from piperazinepropionic acid (II) by boiling 2 hr with SOCl2, 2 hr with Br-CHCl3, and 5 hr with EtOH. The experimental process involved the reaction of 3-(4-Methylpiperazin-1-yl)propanoic acid dihydrochloride(cas: 59695-29-3).Formula: C8H18Cl2N2O2

The Article related to piperazine thiooxalylbismethyl, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines and other aspects.Formula: C8H18Cl2N2O2

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Mrachkovskaya, L. B.; Turchin, K. F.; Yakhontov, L. N. published an article in 1975, the title of the article was Reduction fragmentation of 4-methyl-1-piperazinylmethylidenemalonate.Quality Control of 3-(4-Methylpiperazin-1-yl)propanoic acid dihydrochloride And the article contains the following content:

Di-Et 4-methyl-1-piperazinylmethylidenemalonate (I), prepared in 83.5% yield from 1-methylpiperazine (II) and EtOCH:C(CO2Et)2, was reductively cleaved by NaBH4 in absolute EtOH at 20-5掳 to give 65% of a mixture of II and methylmalonic acid (III). Analogous reduction in dioxane gave 11% II-III and in cyclohexane 5% II-III were obtained. Similar results were obtained by catalytic reduction with Pt. The experimental process involved the reaction of 3-(4-Methylpiperazin-1-yl)propanoic acid dihydrochloride(cas: 59695-29-3).Quality Control of 3-(4-Methylpiperazin-1-yl)propanoic acid dihydrochloride

The Article related to reduction cleavage piperazinylmethylenemalonic acid, pyruvoyl hydrazone reaction hydrazide, triazole acetyl anilino, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines and other aspects.Quality Control of 3-(4-Methylpiperazin-1-yl)propanoic acid dihydrochloride

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 15, 2017, Platania, Chiara Bianca Maria; Giurdanella, Giovanni; Di Paola, Luisa; Leggio, Gian Marco; Drago, Filippo; Salomone, Salvatore; Bucolo, Claudio published an article.COA of Formula: C28H32N4O2S The title of the article was P2X7 receptor antagonism: Implications in diabetic retinopathy. And the article contained the following:

Diabetic retinopathy (DR) is the most frequent complication of diabetes and one of leading causes of blindness worldwide. Early phases of DR are characterized by retinal pericyte loss mainly related to concurrent inflammatory process. Recently, an important link between P2X7 receptor (P2X7R) and inflammation has been demonstrated indicating this receptor as potential pharmacol. target in DR. Here the authors first carried out an in silico mol. modeling study in order to characterize the allosteric pocket in P2X7R, and identify a suitable P2X7R antagonist through mol. docking. JNJ47965567 was identified as the hit compound in docking calculations, as well as for its absorption, distribution, metabolism and excretion (ADME) profile. As an in vitro model of early diabetic retinopathy, human retinal pericytes were exposed to high glucose (25 mM, 48 h) that caused a significant (p < 0.05) release of IL-1尾 and LDH. The block of P2X7R by JNJ47965567 significantly (p < 0.05) reverted the damage elicited by high glucose, detected as IL-1尾 and LDH release. Overall, the findings suggest that the P2X7R represents an attractive pharmacol. target to manage the early phase of diabetic retinopathy, and the compound JNJ47965567 is a good template to discover other P2X7R selective antagonists. The experimental process involved the reaction of N-((4-(4-Phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide(cas: 1428327-31-4).COA of Formula: C28H32N4O2S

The Article related to p2x7 receptor antagonism diabetic retinopathy, diabetic retinopathy, il-1尾, inflammation, molecular modeling, p2x7 receptor, pericytes, Pharmacology: Effects Of Agents For Treating Metabolic and Endocrine Disorders and other aspects.COA of Formula: C28H32N4O2S

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 31, 1977, Saikawa, Isamu; Takano, Shuntaro; Yoshida, Chosaku; Takashima, Okuta; Momonoi, Kaishu; Yasuda, Takashi; Kasuya, Kyoko published an article.Name: 4-Ethyl-piperazine-1-carbonyl chloride The title of the article was Studies on 尾-lactam antibiotics for medicinal purposes. I. Synthesis of D(-)-伪-[(monooxo)-1-piperazinecarboxamido]benzylpenicillins and structure-antibacterial activity. And the article contained the following:

D-(-)-I (R1 = Me, Et, PhCH2, Ac, MeSO2, Ph), D-(-)-II (R1 = C1-4 alkyl, PhCH2, Ac, EtCO, PrCO, BuCO, ClCH2CO, MeSO2), and D-(-)-III (R1 = H, C1-4 alkyl, PhCH2, allyl) were prepared by N-acylation of aminobenzylpenicillin (IV). In vitro bactericidal activity of I – III against S. aureus, E. coli, P. aeruginosa, P. vulgaris, and K. pneumoniae decreased in the order of II > I > III. The bactericidal activity of these compounds against P. aeruginosa and K. pneumoniae was stronger than that of IV or carbenicillin. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).Name: 4-Ethyl-piperazine-1-carbonyl chloride

The Article related to bactericides piperazinecarboxamidobenzylpenicillin, piperazinecarboxamidobenzylpenicillin, penicillin piperazinecarboxamidobenzyl, benzylpenicillin piperazinecarboxamido, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines and other aspects.Name: 4-Ethyl-piperazine-1-carbonyl chloride

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics